Table 2.
Multivariable Analysis of Engraftment, Relapse and Non-Relapse Mortality
| Neutrophil Engraftment* | Relapse† | Non-Relapse Mortality‡ | ||||||
|---|---|---|---|---|---|---|---|---|
| N | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | P | ||
| Age | <60 | 144 | Reference | 0.058 | Reference | 0.75 | Reference | 0.005 |
| ≥60 | 66 | 0.72(0.52,1.01) | 0.89(0.46,1.75) | 3.42(1.45,8.07) | ||||
| Sex | M | 122 | Reference | 0.57 | Reference | 0.054 | Reference | 0.096 |
| F | 88 | 1.08(0.83,1.42) | 0.56(0.31,1.01) | 1.65(0.92,2.97) | ||||
| Female donor to male recipient | No | 176 | Reference | 0.83 | Reference | 0.16 | Reference | 0.42 |
| Yes | 34 | 0.97(0.71,1.32) | 1.59(0.83,3.04) | 0.71(0.31,1.63) | ||||
| Disease Risk Index | Low | 31 | Reference | 0.26 | Reference | 0.014 | Reference | 0.14 |
| Intermediate | 81 | 0.74(0.51,1.06) | 4.01(0.99,16.29) | 3.23(0.97,10.73) | ||||
| High/Very high | 78 | 0.84(0.58,1.22) | 5.47(1.59,18.77) | 3.18(0.97,10.49) | ||||
| Conditioning regimen | MAC-TBI | 71 | Reference | 0.51 | Reference | 0.21 | Reference | 0.77 |
| MAC-NonTBI | 18 | 1.01(0.61,1.68) | 0.23(0.05,1.19) | 0.61(0.14,2.68) | ||||
| RIC/NMA | 121 | 0.83(0.57,1.20) | 0.75(0.39,1.44) | 0.80(0.30,2.12) | ||||
| Donor type | Haploidentical | 172 | Reference | 0.058 | Reference | 0.076 | Reference | 0.57 |
| Mismatched unrelated | 38 | 1.40(0.99,1.99) | 0.34(0.10,1.12) | 1.23(0.60,2.49) | ||||
| ABO blood group compatibility | ABO Compatible | 139 | Reference | 0.18 | Reference | 0.63 | Reference | 0.29 |
| Minor | 32 | 1.50(1.04,2.17) | 0.98(0.52,1.86) | 0.31(0.09,1.05) | ||||
| Major | 24 | 1.05(0.75,1.49) | 0.50(0.17,1.43) | 0.75(0.31,1.79) | ||||
| Bidirectional | 15 | 1.18(0.70,1.99) | 0.97(0.32,2.96) | 0.94(0.31,2.87) | ||||
| Donor CMV serostatus | D+ | 143 | Reference | 0.74 | Reference | 0.48 | Reference | 0.23 |
| D− | 67 | 1.05(0.79,1.40) | 1.23(0.69,2.17) | 0.66(0.34,1.30) | ||||
| Recipient CMV serostatus | R+ | 177 | Reference | 0.70 | Reference | 0.81 | Reference | 0.30 |
| R− | 33 | 1.09(0.70,1.70) | 0.90(0.38,2.13) | 0.59(0.21,1.61) | ||||
| Graft source | Peripheral blood stem cells | 166 | Reference | 0.047 | Reference | <0.001 | Reference | 0.47 |
| Bone marrow | 44 | 0.70(0.50,1.00) | 3.63(1.81,7.29) | 0.73(0.32,1.68) | ||||
| Karnofsky Performance Status, % | ≥80 | 176 | Reference | 0.76 | Reference | 0.37 | Reference | 0.13 |
| <80 | 34 | 0.94(0.63,1.40) | 1.41(0.66,2.99) | 1.69(0.86,3.32) | ||||
| HCT-Comorbidity Index | 0–2 | 125 | Reference | 0.037 | Reference | 0.85 | Reference | 0.16 |
| ≥3 | 85 | 0.74(0.56,0.98) | 1.05(0.62,1.81) | 1.51(0.85,2.68) | ||||
| Tacrolimus initial dosing method | Flat | 131 | Reference | 0.59 | Reference | 0.34 | Reference | 0.41 |
| Weight-based | 79 | 1.08(0.82,1.43) | 1.31(0.75,2.27) | 1.27(0.72,2.25) | ||||
| Tacrolimus at initial steady state, ng/mL | <10 | 176 | Reference | 0.36 | Reference | 0.53 | Reference | 0.80 |
| ≥10 | 34 | 0.83(0.56,1.23) | 1.25(0.62,2.52) | 1.11(0.49,2.54) | ||||
*
Adjusted for Age, Graft source, HCT-Comorbidity Index and Conditioning regimen
†
Adjusted for Disease Risk Index, Graft source and Conditioning regimen
‡
Adjusted for Age and Conditioning regimen